Kiran Mazumdar Shaw, a prominent figure in biotechnology, initially aspired to be a doctor but faced disappointment when she did not gain admission to medical school. During a 2015 event at the Indian Institute of Management Bangalore, Dr. Devi Shetty, founder of Narayana Health, reflected on how this setback led Shaw to shift her focus from treating individual patients to addressing broader healthcare issues. This redirection resulted in the establishment of Biocon, a company that has significantly impacted the availability of affordable medicines, particularly insulin for diabetes patients. Shetty remarked that had Shaw pursued a traditional medical career, her influence would have been limited to a small number of patients. Instead, her entrepreneurial journey has transformed the biotechnology sector in India, benefiting millions. Shaw, who began her venture in 1978, has built Biocon into a global player in biotech, emphasizing accessible healthcare. With an estimated net worth of ₹30,000 crore (approximately $3.6 billion USD), she continues to lead Biocon while preparing her successor, Claire Mazumdar, who holds impressive academic credentials in biological engineering and cancer biology.